Biogen reaches fresh 52-week high, shares extend strong S&P 500 run

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 13:42.

Biogen Inc. (US09062X1037) has pushed to a new 52-week high around 206 dollars on NASDAQ, according to an Investing.com market report citing a 61 percent gain over the past 12 months. The biotechnology group thereby outperforms many S&P 500 healthcare names such as AbbVie and Amgen in the year-on-year comparison.

What the latest high reflects

The new 52-week peak at 206.21 dollars marks the highest level for Biogen shares in the past year and caps a period of strong momentum for the stock. Investing.com notes that Biogen’s market capitalization now stands at roughly 30.3 billion dollars, with the shares placed on its "Most Undervalued" list based on a proprietary fair value estimate.

The report adds that Biogen’s share price advance of about 61.26 percent over twelve months points to robust investor confidence in the company’s earnings outlook and pipeline. The company has simultaneously expanded its late-stage portfolio in competition with peers such as Eli Lilly and Roche in neurology and immunology.

Analyst houses stay constructive

Following recent corporate moves, Needham has reiterated a Buy rating on Biogen and set a price target of 255 dollars, according to the same Investing.com summary. The analysts highlight expectations for roughly 2 percent compound annual revenue growth over the next five years, supported by Biogen’s commercial portfolio and pipeline. Cantor Fitzgerald is cited with an Overweight stance on the BIIB080 program, underlining continued support from another major Wall Street house.

Biogen also recently announced the acquisition of a biotechnology company referred to as RayThera, with a deal structure of up to 1 billion dollars in upfront and milestone payments, as reported by Investing.com. The transaction adds several anti-inflammatory assets, with the lead candidate slated to enter Phase 1 trials in early third quarter 2026, which could further diversify Biogen’s development slate. The Investing.com article on Biogen’s 52-week high and analyst views summarizes these points.

The therapies behind the stock

Biogen generates most of its revenue with therapies in neurology and rare diseases, including multiple sclerosis drugs such as Tecfidera and Tysabri, as well as spinal muscular atrophy treatment Spinraza. In Alzheimer’s disease, the company co-developed monoclonal antibodies like Leqembi together with Eisai, targeting beta-amyloid pathology in early stages of the condition. Beyond neurology, Biogen is expanding into immunology and neuropsychiatry with a pipeline of biologics and antisense oligonucleotides developed jointly with partners such as Ionis Pharmaceuticals.

Where the shares trade today

Biogen shares (US09062X1037) trade on NASDAQ under the ticker BIIB; around mid-day U.S. time on 2026-06-26 they recently changed hands at approximately 206 dollars, close to the cited 52-week high of 206.21 dollars. This implies an equity value in the low-30-billion-dollar range for the biotechnology group.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities.